Sign inJoin waitlistJoin the waitlist

David Shulman

AYA Sarcoma Program Director · Mass General Brigham

Credentials: · · · ·

History

AYA Sarcoma · Mass General Brigham
Present
Mass General Brigham
Present

Dana-Farber Cancer Institute
2016–2017
Pediatrics
Boston Children's Hospital
2013–2016
Harvard Medical School
2009–2013

Research

Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Review · Journal of Clinical Medicine · 2021 · 195 citations
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities
Nature Medicine · 2013 · 128 citations
Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group
British Journal of Cancer · 2018 · First of 21 authors · 120 citations

Steven DuBois
36 papers
Katherine Janeway
21 papers
Brian Crompton
20 papers
DR
Damon Reed
7 papers
Natalie Collins
6 papers
Alanna Church
5 papers
Allison O'Neill
5 papers
LM
Leo Mascarenhas
5 papers
PG
Patrick Grohar
5 papers
Patrick Leavey
5 papers
Richard Gorlick
5 papers
Andrew Place
4 papers

Grants

Validation and Implementation of ctDNA as a Clinically Informative Biomarkerin AYAs with Sarcomas.
National Cancer Institute · K08
Contact PI · $760.4K · Dana-Farber Cancer Inst
2024–2029

Clinical trials

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Principal investigator · Recruiting · Phase 1, Phase 2
David S Shulman, MD
2025–2029
Palbociclib + Ganitumab In Ewing Sarcoma
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute
2019–2022
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
2018–2023
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
Principal investigator · Active not recruiting
Dana-Farber Cancer Institute
2018–2027